Synovial fibroblast niche shapes the efficacy–safety dynamics of JAK inhibition in rheumatoid arthritis

Read full text Summarise with VIRAT
Authors: Ana Županič, Sam G. Edalat, Blaž Burja, Miriam Paulina Busch, Tadeja Kuret, Nadja Ižanc, R. S. Zingg, Laura M. Merlo Pich, Snežna Sodin‐Šemrl, Oliver Distler, Miranda Houtman, Caroline Ospelt
+3 more Reto Gerber, Mark D. Robinson, Mojca Frank‐Bertoncelj
Cited by: 0
References: 68

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Abstract Synovial fibroblasts (SF) drive joint pathology in rheumatoid arthritis (RA). Difficult-to-treat RA frequently exhibits a fibroblast-rich synovial pathotype, enriched in DKK3□ and CD34□ SF, highlighting a critical therapeutic gap. Through multicohort transcriptomic analysis of synovial tissues and mechanistic in vitro studies, we identified SF as principal targets of Janus kinase (JAK) inhibition in RA. We demonstrated that JAK inhibitors (JAKi) can target multiple core aspects of fibroblast pathobiology – therapeutic refractoriness, cartilage destruction, and inflammation – offering a mechanistic rationale for JAKi superiority in difficult-to-treat RA. JAK1 was the dominantly expressed JAK across synovial pathotypes and SF subsets, including DKK3□ and CD34□ populations. A STAT1–interferon type I gene program was enriched in matrix-destructive PRG4□ SF, consistent with JAKi efficacy in erosive RA. In contrast, canonical IL-6 signaling predominated in IL6–expressing inflammatory CXCL12 high and HLA-DR+ SF, and was reproduced in cytokine-stimulated cultured SF, underscoring the autocrine nature of synovial IL-6 signaling. These data inferred a heightened JAKi sensitivity of PRG4□, CXCL12 high , and HLA-DR+ SF subsets, informing precision therapeutic strategies. We uncovered a strong synergy between TNF and IL-6 trans-signaling, profoundly amplifying fibroblast inflammation. In high and synergistic cytokine milieu, STAT1/3 phosphorylation and IL-6 secretion persisted in SF despite tofacitinib treatment, revealing tofacitinib’s functional ceiling. This could explain reduced tofacitinib efficacy and adherence in patients with high baseline arthritis activity. Finally, inflamed SF partially uncoupled STAT3 activation from sustained JAK1 phosphorylation, limiting inflammatory output. Similar uncoupling in tofacitinib-treated SF, likely drove rapid STAT1/3 reactivation following tofacitinib washout. These data aligned with JAKi withdrawal complications and clinical recommendations for gradual JAKi tapering. Collectively, our study identifies SF as key cellular targets of JAK inhibition and delineates cytokine– and drug-driven mechanisms that may constrain the efficacy and safety profiles of JAKi in RA.

Fields of Study & Subjects

Rheumatoid Arthritis Research and Therapies Cytokine Signaling Pathways and Interactions Autoimmune and Inflammatory Disorders Research

Publication details

Journal / source
bioRxiv (Cold Spring Harbor Laboratory)
Publication date
25 March 2026
Language
EN
Document type
Preprint